New Zealand Formulary
Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

Home > Breast

Breast Regimens



Metastatic Regimens


Published

Name Sort
Id Sort
Version Sort
Date Sort
BR Advanced/Metastatic - abemaciclib
392981000210109
1.0.0
24/07/2024
BR Metastatic - Abraxane [PACLItaxel nanoparticle albumin bound] [Q1W 2/3]
59791000210109
1.0.0
01/09/2022
BR Metastatic - Abraxane [PACLItaxel nanoparticle albumin bound] [Q1W 3/4]
59831000210103
1.0.0
01/09/2022
BR Metastatic - Abraxane [PACLItaxel nanoparticle albumin bound] and aTEZOLIzumab
58481000210105
2.0.0
22/04/2022
BR Metastatic - AC [DOXOrubicin and CYCLOPHOSPHamide]
59131000210109
2.0.0
24/08/2026
BR Metastatic - alpelisib and fulvestrant
506891000210102
1.0.0
12/05/2026
BR Metastatic - capecitabine 1000
52581000210108
1.0.0
29/06/2021
BR Metastatic - capecitabine 1000 and trastuzumab Q3W
59191000210105
1.0.0
22/04/2022
BR Metastatic - capecitabine 1000, trastuzumab and tucatinib
393191000210100
1.0.0
16/08/2024
BR Metastatic - capecitabine 1250
58671000210105
1.0.0
16/11/2021
BR Metastatic - capecitabine 1500 [flat dosing] [7-days on 7-days off]
392961000210101
1.0.0
24/07/2024
BR Metastatic - capecitabine 750 and neratinib
392971000210107
1.0.0
24/07/2024
BR Metastatic - cARBOplatin
57791000210102
2.0.0
22/04/2022
BR Metastatic - cARBOplatin [2 AUC] and gemcitabine
392611000210105
1.0.0
29/05/2024
BR Metastatic - cARBOplatin [5 AUC] and gemcitabine
58601000210103
3.0.0
30/05/2024
BR Metastatic - cARBOplatin [2 AUC], gemcitabine and pembrolizumab
506881000210104
1.0.0
12/05/2026
BR Metastatic - CMF classical [CYCLOPHOSPHamide, metHOTREXATe and fluorouracil]
59811000210105
1.0.0
18/09/2023
BR Metastatic - CMF classical IV [CYCLOPHOSPHamide, metHOTREXATe and fluorouracil]
59301000210102
1.0.0
18/09/2023
BR Metastatic - CYCLOPHOSPHamide and metHOTREXATe [low dose oral]
58881000210108
3.0.0
17/08/2023
BR Metastatic - denosumab
58531000210107
1.0.0
22/10/2021
BR Metastatic - DOCEtaxel and pERTUZumab/trastuzumab subcutaneous [Phesgo]
506871000210101
1.0.0
12/05/2026
BR Metastatic - DOCEtaxel and trastuzumab Q3W
59151000210103
1.0.0
22/04/2022
BR Metastatic - DOCEtaxel, pERTUZumab and trastuzumab
59171000210106
1.0.0
22/04/2022
BR Metastatic - DOCEtaxel Q3W
59181000210108
1.0.0
22/04/2022
BR Metastatic - DOXOrubicin Q1W
58611000210101
1.0.0
18/09/2023
BR Metastatic - DOXOrubicin Q3W
58641000210100
1.0.0
22/10/2021
BR Metastatic - EC [epirubicin and CYCLOPHOSPHamide]
57781000210104
2.0.0
24/08/2026
BR Metastatic - eribulin
58631000210108
1.0.0
22/10/2021
BR Metastatic - everolimus and exemestane
58491000210107
1.0.0
22/10/2021
BR Metastatic - fulvestrant
58541000210104
1.0.0
22/10/2021
BR Metastatic - gemcitabine
58591000210108
1.0.0
22/10/2021
BR Metastatic - goserelin Q12W
58561000210103
1.0.0
22/10/2021
BR Metastatic - goserelin Q4W
57801000210103
1.0.0
22/10/2021
BR Metastatic - Kadcyla [trastuzumab emtansine]
58511000210100
1.0.0
22/10/2021
BR Metastatic - MMM [mitomycin, mitoxantrone and metHOTREXATe]
58521000210105
2.0.0
22/04/2022
BR Metastatic - olaparib
264201000210108
1.0.0
19/04/2023
BR Metastatic - PACLItaxel nanoparticle albumin bound [Abraxane] [Q1W 2/3] and pembrolizumab Q3W
506861000210107
1.0.0
12/05/2026
BR Metastatic - PACLItaxel Q1W
58501000210102
2.0.0
22/04/2022
BR Metastatic - PACLItaxel Q1W and pembrolizumab Q3W
506851000210109
1.0.0
12/05/2026
BR Metastatic - PACLItaxel Q1W and pERTUZumab/trastuzumab subcutaneous Q3W [Phesgo]
506841000210106
1.0.0
12/05/2026
BR Metastatic - PACLItaxel Q1W and trastuzumab Q3W
58581000210106
1.0.0
22/10/2021
BR Metastatic - PACLItaxel Q1W, pERTUZumab and trastuzumab Q3W
58621000210106
1.0.0
22/10/2021
BR Metastatic - palbociclib
57811000210101
1.0.0
22/10/2021
BR Metastatic - pamidronate
58571000210109
1.0.0
22/10/2021
BR Metastatic - pembrolizumab Q3W [flat dosing]
58551000210101
1.0.0
22/10/2021
BR Metastatic - ribociclib
392601000210108
1.0.0
29/05/2024
BR Metastatic - sacituzumab govitecan
393181000210102
2.0.0
08/05/2026
BR Metastatic - trastuzumab deruxtecan [Enhertu]
393401000210104
2.0.0
12/05/2026
BR Metastatic - trastuzumab Q3W
58651000210102
1.0.0
22/10/2021
BR Metastatic - trastuzumab Q3W and vinORELBine [IV]
58461000210102
1.0.0
22/10/2021
BR Metastatic - trastuzumab Q3W and vinORELBine [oral]
58471000210108
1.0.0
18/09/2023
BR Metastatic - trastuzumab subcutaneous
57831000210108
1.0.0
22/10/2021
BR Metastatic - vinORELBine [IV]
57821000210106
1.0.0
22/10/2021
BR Metastatic - vinORELBine [oral]
59781000210107
1.0.0
01/09/2022
BR Metastatic - vinORELBine [IV], pERTUZumab and trastuzumab Q3W
59801000210108
1.0.0
01/09/2022
BR Metastatic - vinORELBine [oral], pERTUZumab and trastuzumab Q3W
393411000210102
1.0.0
26/08/2024
BR Metastatic - vinORELBine [IV] Q1W
57771000210101
1.0.0
22/10/2021
BR Metastatic - zoledronic acid Q12W
58841000210101
1.0.0
16/11/2021
BR Metastatic - zoledronic acid Q4W
58701000210109
1.0.0
16/11/2021

Discontinued Regimens

Name
Id
Version
Published date
BR Metastatic - Abraxane [PACLItaxel nanoparticle albumin bound] Q3W
58771000210102
1.1.4
20/08/2025

NON-metastatic Regimens


Published

Name Sort
Id Sort
Version Sort
Date Sort
BR Adjuvant - abemaciclib
393011000210107
1.0.0
24/07/2024
BR Adjuvant - AC [DOXOrubicin and CYCLOPHOSPHamide] dose dense followed by PACLItaxel dose dense
58861000210100
4.0.0
24/08/2026
BR Adjuvant - AC [DOXOrubicin and CYCLOPHOSPHamide] Q3W followed by PACLItaxel Q1W and trastuzumab Q3W
58681000210107
4.0.0
24/08/2026
BR Adjuvant - AC-TH [DOXOrubicin and CYCLOPHOSPHamide] Q3W followed by [DOCEtaxel and trastuzumab] Q3W
59121000210107
4.0.0
24/08/2026
BR Adjuvant - capecitabine
58851000210103
2.0.0
06/08/2024
BR Adjuvant - capecitabine [metronomic]
393001000210105
1.0.0
24/07/2024
BR Adjuvant - CMF classical [CYCLOPHOSPHamide, metHOTREXATe and fluorouracil]
58871000210106
3.0.0
06/08/2024
BR Adjuvant - CMF classical IV [CYCLOPHOSPHamide, metHOTREXATe and fluorouracil]
59311000210100
3.0.0
06/08/2024
BR Adjuvant - EC [epirubicin and CYCLOPHOSPHamide]
264161000210101
3.0.0
24/08/2026
BR Adjuvant - EC-D [epirubicin and CYCLOPHOSPHamide followed by DOCEtaxel]
264211000210105
3.0.0
24/08/2026
BR Adjuvant - exemestane and goserelin
58801000210104
2.0.0
06/08/2024
BR Adjuvant - Kadcyla [trastuzumab emtansine]
58721000210101
2.0.0
06/08/2024
BR Adjuvant - neratinib
58751000210105
1.0.0
06/08/2024
BR Adjuvant - olaparib
392991000210106
1.0.0
24/07/2024
BR Adjuvant - PACLItaxel Q1W and trastuzumab Q3W
58791000210103
3.0.0
06/08/2024
BR Adjuvant - ribociclib
506921000210109
1.0.0
12/05/2026
BR Adjuvant - TAMoxifen
506911000210104
1.0.0
12/05/2026
BR Adjuvant - TAMoxifen and goserelin
506901000210101
1.0.0
12/05/2026
BR Adjuvant - TCH [DOCEtaxel, cARBOplatin and trastuzumab]
58741000210107
3.0.0
06/08/2024
BR Adjuvant - TCy [DOCEtaxel and CYCLOPHOSPHamide]
58711000210106
2.0.0
06/08/2024
BR Adjuvant - TCy and trastuzumab [DOCEtaxel, CYCLOPHOSPHamide and trastuzumab]
58831000210109
2.0.0
06/08/2024
BR Adjuvant - zoledronic acid
58761000210108
2.0.0
03/04/2025
BR Neoadjuvant - AC [DOXOrubicin and CYCLOPHOSPHamide] Q3W followed by DOCEtaxel Q3W
58661000210104
4.0.0
24/08/2026
BR Neoadjuvant/Adjuvant - AC [DOXOrubicin and CYCLOPHOSPHamide] dose dense
57761000210107
2.0.0
24/08/2026
BR Neoadjuvant/Adjuvant - AC [DOXOrubicin and CYCLOPHOSPHamide] Q3W
57841000210100
3.0.0
24/08/2026
BR Neoadjuvant/Adjuvant - AC [DOXOrubicin and CYCLOPHOSPHamide] Q3W followed by PACLItaxel Q1W
59161000210100
4.0.0
24/08/2026
BR Neoadjuvant/Adjuvant - cARBOplatin [5 AUC] Q3W and PACLItaxel Q1W followed by AC [DOXOrubicin and CYCLOPHOSPHamide] Q3W with pembrolizumab Q3W
components ▾
393431000210109
1.0.0
26/08/2024
cARBOplatin [5 AUC] Q3W, PACLItaxel Q1W with pembrolizumab Q3W
393441000210101
0.0.13
AC [DOXOrubicin and CYCLOPHOSPHamide] with pembrolizumab Q3W
393451000210103
0.0.6
Adjuvant pembrolizumab Q3W
393461000210100
0.0.3
BR Neoadjuvant/Adjuvant - D100-FEC [DOCEtaxel followed by fluorouracil, epirubicin and CYCLOPHOSPHamide]
264191000210106
3.0.0
24/08/2026
BR Neoadjuvant/Adjuvant - D75-FEC [DOCEtaxel followed by fluorouracil, epirubicin and CYCLOPHOSPHamide]
264171000210107
3.0.0
24/08/2026
BR Neoadjuvant/Adjuvant - FEC-D100 [fluorouracil, epirubicin and CYCLOPHOSPHamide followed by DOCEtaxel]
58781000210100
5.0.0
24/08/2026
BR Neoadjuvant/Adjuvant - FEC-D75 [fluorouracil, epirubicin and CYCLOPHOSPHamide followed by DOCEtaxel]
59141000210101
5.0.0
24/08/2026
BR Neoadjuvant/Adjuvant - PACLItaxel Q1W
58731000210104
3.0.0
12/06/2025
BR Neoadjuvant/Adjuvant - trastuzumab Q3W
58821000210107
1.0.0
19/08/2024
BR Neoadjuvant/Adjuvant - trastuzumab subcutaneous
58811000210102
1.0.0
19/08/2024
BR Neoadjuvant - CARBOplatin, PACLItaxel, pERTUZumab and trastuzumab
506391000210108
1.0.0
04/05/2025
BR Neoadjuvant - cARBOplatin Q1W and PACLItaxel Q1W
392951000210104
1.0.0
24/07/2024
BR Neoadjuvant - cARBOplatin Q3W and PACLItaxel Q1W followed by AC [DOXOrubicin and CYCLOPHOSPHamide] dose dense
59821000210100
2.0.0
24/08/2026
BR Neoadjuvant - cARBOplatin Q3W and PACLItaxel Q1W followed by AC [DOXOrubicin and CYCLOPHOSPHamide] Q3W
264181000210109
3.0.0
24/08/2026
BR Neoadjuvant - DOCEtaxel and trastuzumab followed by FEC [fluorouracil, epirubicin and CYCLOPHOSPHamide] followed by trastuzumab
components ▾
393021000210102
1.0.0
24/07/2024
DOCEtaxel and trastuzumab
393031000210100
0.0.9
FEC [fluorouracil, epirubicin and CYCLOPHOSPHamide]
393041000210108
0.0.6
Adjuvant trastuzumab
393051000210106
0.0.5
BR Neoadjuvant - DOCEtaxel, pERTUZumab and trastuzumab
59841000210106
2.0.0
06/08/2024
BR Neoadjuvant - PACLItaxel Q1W, pERTUZumab and trastuzumab Q3W
57851000210102
3.0.0
23/05/2025

Discontinued Regimens

Name
Id
Version
Published date
BR NON-Metastatic - cARBOplatin Q3W and PACLItaxel Q1W
58691000210109
1.2.2
20/08/2025